We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Modafinil (Provigil) — wakefulness-promoting agent
A prescription wakefulness-promoting drug (Provigil) approved for the excessive daytime sleepiness of narcolepsy, shift-work sleep disorder, and residual sleepiness in treated obstructive sleep apnea. Widely used off-label as a 'smart drug' for cognition, but the cognitive benefit in healthy people is modest and task-dependent — and it carries a rare but serious skin-reaction (SJS/TEN) warning. A prescription drug, not a supplement, and not a longevity drug.
Prescription medication — not a dietary supplement
Modafinil is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Modafinil doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 1998–2026 with a typical study size of 271 participants.
Based on 46 studies · 12 meta-analyses · 17 RCTs · 763 total participants
Confidence
High confidenceBy outcome
Modafinil has strong pivotal-RCT evidence for its approved sleep-disorder indications (narcolepsy, shift-work sleep disorder, residual sleepiness in treated OSA), but the popular off-label cognitive-enhancement use is supported only by modest, task-dependent effects in healthy adults (largest meta-analysis overall effect ~0.12), it is not a longevity drug, and it carries a rare but serious skin-reaction (SJS/TEN) warning — so the off-label use stays emerging.
24 randomised trials
75% were about Modafinil in an audit of 24 of them
Every randomised or controlled trial of Modafinil indexed in PubMed, not a hand-picked subset. Meta-analyses and systematic reviews are deliberately excluded from this count: most of them cover many compounds at once, so counting them would inflate it.
PubMed · as of Sep 2026
17 trials ongoing or recruiting · 150 completed on ClinicalTrials.gov
76 of the completed trials have posted results
Registered trials show research momentum for Modafinil, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Nov 2026
Modafinil is a eugeroic — a wakefulness-promoting agent — that increases cortical catecholamine tone and indirectly raises orexin, histamine, glutamate, and serotonin signalling while lowering GABA, producing alertness through a profile distinct from amphetamine.
Its approved uses are well-evidenced: pivotal placebo-controlled RCTs in narcolepsy (the US Modafinil in Narcolepsy trials), in shift-work sleep disorder (Czeisler, NEJM 2005), and as an adjunct for residual excessive sleepiness in CPAP-treated obstructive sleep apnea (Black & Hirshkowitz, 2005) all show significant reductions in objective and subjective sleepiness.
Off-prescription, modafinil is taken widely as a cognitive enhancer or 'smart drug', and this is where the honest distinction matters: systematic reviews and meta-analyses in healthy, non-sleep-deprived adults find the cognitive benefit is MODEST and TASK-DEPENDENT — most consistent for executive function, attention, and memory updating under demanding or sleep-deprived conditions, smaller and inconsistent for simple tasks, with the largest 2020 meta-analysis reporting an overall effect size of only ~0.12 and concluding the user perception of strong enhancement 'is not supported by the evidence.' Modafinil is not a longevity or healthspan drug — there is no lifespan or geroprotective evidence.
Its abuse and dependence liability is low relative to classic stimulants, but it is not benign: the US label carries a serious warning for rare but life-threatening skin reactions (Stevens-Johnson syndrome and toxic epidermal necrolysis), plus psychiatric effects, and it induces CYP3A4 (reducing hormonal contraceptive efficacy).
The score reflects genuinely strong evidence for its approved sleep-disorder indications against a modest, task-dependent off-label cognitive benefit and real serious-rash risk.
Increases cortical catecholamine levels (weak dopamine-transporter inhibition raising synaptic dopamine and noradrenaline) — the core of its wake-promoting action.
Indirectly activates orexin (hypocretin) neurons and the tuberomammillary histamine system, engaging the brain's intrinsic arousal pathways.
Effects favour prefrontal-dependent processes — working/episodic memory and executive control — over subcortical sites, underlying the task-dependent cognitive effects.
How Modafinil works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Use additional/alternative contraception during and for ~1 month after modafinil (CYP3A4 induction lowers efficacy).
Use with caution — modafinil can precipitate mania, psychosis, or anxiety.
Caution with uncontrolled hypertension or arrhythmia; monitor blood pressure and heart rate.
Modafinil induces CYP3A4 and can reduce contraceptive efficacy — additional/alternative contraception is advised during and for ~1 month after use.
Inhibits CYP2C19 and alters other enzymes — can raise levels of warfarin, phenytoin, and similar drugs; monitor.
Additive cardiovascular and CNS stimulation; use with caution.
Tip: Most frequent adverse effect in trials; often dose-related and transient.
Tip: Contact your treating team about the symptom and follow the product-specific instructions. Do not reduce, split, stop or restart prescribed treatment solely to continue this experiment.
Tip: Stop immediately and seek emergency care at the first sign of rash, blistering, or mucosal involvement; risk is highest early in treatment.
Tip: Caution in those with a psychiatric history; discontinue and seek care if new psychiatric symptoms emerge.
Modafinil has an evidence score of 5/10 — moderate evidence based on 46 indexed studies, including 1 meta-analysis. A prescription wakefulness-promoting drug (Provigil) approved for the excessive daytime sleepiness of narcolepsy, shift-work sleep disorder, and residual sleepiness in treated obstructive sleep apnea. Widely used off-label as a 'smart drug' for cognition, but the cognitive benefit in healthy people is modest and task-dependent — and it carries a rare but serious skin-reaction (SJS/TEN) warning. A prescription drug, not a supplement, and not a longevity drug. Representative study: PMID 32709551.
Dosing for Modafinil: Approved dosing is 200 mg once daily in the morning for narcolepsy and OSA, or 200 mg taken ~1 hour before the start of a night shift for shift-work sleep disorder. A prescription drug; off-label cognitive use is not an approved or standardized regimen. Individual needs vary, so check the right dose for you with a healthcare provider.
The best time to take Modafinil is in the morning. It can be taken on an empty stomach. Long half-life (~12–15 h) means morning dosing avoids disrupting nighttime sleep; shift-work use is dosed before the shift.
Modafinil should be used with caution — talk to a healthcare provider before taking it. Reported side effects include serious skin reaction (Stevens-Johnson syndrome / TEN), psychiatric effects (mania, psychosis, suicidal ideation), headache. How often they occur is not established for all of them. Use caution if any of these apply to you: Prior hypersensitivity or serious skin reaction to modafinil/armodafinil; History of left ventricular hypertrophy or mitral valve prolapse with prior stimulant use; Uncontrolled hypertension or arrhythmia (use with caution).
Caffeine
Probably helpsBlocks adenosine receptors to boost alertness, reaction time, and endurance — an umbrella review of 21 meta-analyses found it ergogenic for endurance, strength and power.
Nicotinamide Riboside
Too few graded studiesA vitamin B3 precursor that reliably raises cellular NAD+ levels and is well tolerated — but human trials have so far shown mostly null or mixed results on the functional outcomes (muscle, metabolism, blood pressure, cognition) that elevation is meant to drive.
CoQ10
Likely helpsA lipid-soluble antioxidant central to mitochondrial energy production, with the strongest trial support for fertility/IVF outcomes and heart failure.
Citicoline
Probably helpsPrecursor to acetylcholine and phosphatidylcholine. One trial in 100 healthy older adults improved memory. Stroke trials are mixed.
Explore: Best supplements for Focus, Memory & MoodBest supplements for Athletic Performance
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 46 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research